Journal article
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Journal of hematology and oncology, Vol.15(1), pp.1-96
07/16/2022
DOI: 10.1186/s13045-022-01316-1
PMCID: PMC9287914
PMID: 35842643
Abstract
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study and divided the study population into three groups: “ibrutinib responders”—patients who achieved complete or partial response (CR/PR) to ibrutinib; “stable disease (SD)”; and “primary progressors (PP)”—patients with progression of disease as their best response to ibrutinib. One hundred and nineteen patients met the eligibility criteria with 58%/17% ORR/CR, 29% with SD, and 13% with PP. The median PFS and OS were 29 and 71.4 months, respectively, with no difference in PFS or OS based on the ibrutinib line of therapy or type of therapy before ibrutinib. Patients with complex cytogenetics had an inferior PFS (HR = 3.08, 95% CI 1.23–7.67, p = 0.02), while those with both complex cytogenetics (HR = 3.00, 95% CI 1.03–8.68, p = 0.04) and PP (HR = 13.94, 95% CI 5.17–37.62, p < 0.001) had inferior OS. Only primary refractory disease to first-line therapy predicted a higher probability of PP to ibrutinib (RR = 3.77, 95% CI 1.15–12.33, p = 0.03). In this largest study to date evaluating outcomes of R/R MZL treated with ibrutinib, we show that patients with primary refractory disease and those with PP on ibrutinib are very high-risk subsets and need to be prioritized for experimental therapies.
Details
- Title: Subtitle
- Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
- Creators
- Narendranath Epperla - The Ohio State UniversityQiuhong Zhao - The Ohio State UniversitySayan Mullick Chowdhury - The Ohio State UniversityLauren Shea - Washington University in St. LouisTamara K. Moyo - Levine Cancer InstituteNishitha Reddy - Vanderbilt University Medical CenterJulia Sheets - University of North Carolina at Chapel HillDavid M. Weiner - University of PennsylvaniaPraveen Ramakrishnan Geethakumari - The University of Texas Southwestern Medical CenterMalathi Kandarpa - University of MichiganXimena Jordan Bruno - University of VermontColin Thomas - Thomas Jefferson UniversityMichael C. Churnetski - Emory UniversityAndrew Hsu - Brown UniversityLuke Zurbriggen - University of Wisconsin–MadisonCherie Tan - Rutgers Cancer InstituteKathryn Lindsey - Medical University of South CarolinaJoseph Maakaron - University of MinnesotaPaolo F. Caimi - University Hospitals Seidman Cancer CenterPallawi Torka - Roswell Park Cancer InstituteCeleste Bello - Moffitt Cancer CenterSabarish Ayyappan - University of IowaReem Karmali - Northwestern UniversitySeo-Hyun Kim - Rush UniversityAnna Kress - Yale UniversityShalin Kothari - Yale UniversityYazeed Sawalha - The Ohio State UniversityBeth Christian - The Ohio State UniversityKevin A. David - Rutgers Cancer InstituteIrl Brian Greenwell - Medical University of South CarolinaMurali Janakiram - University of MinnesotaVaishalee P. Kenkre - University of Wisconsin–MadisonAdam J. Olszewski - Brown UniversityJonathon B. Cohen - Emory UniversityNeil Palmisiano - Thomas Jefferson UniversityElvira Umyarova - University of VermontRyan A. Wilcox - University of MichiganFarrukh T. Awan - The University of Texas Southwestern Medical CenterJuan Pablo Alderuccio - University of MiamiStefan K. Barta - University of PennsylvaniaNatalie S. Grover - University of North Carolina at Chapel HillNilanjan Ghosh - Levine Cancer InstituteNancy L. Bartlett - Washington University in St. LouisAlex F. Herrera - City Of Hope National Medical CenterGeoffrey Shouse - City Of Hope National Medical Center
- Resource Type
- Journal article
- Publication Details
- Journal of hematology and oncology, Vol.15(1), pp.1-96
- DOI
- 10.1186/s13045-022-01316-1
- PMID
- 35842643
- PMCID
- PMC9287914
- NLM abbreviation
- J Hematol Oncol
- ISSN
- 1756-8722
- eISSN
- 1756-8722
- Publisher
- BioMed Central
- Language
- English
- Date published
- 07/16/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359909302771
Metrics
23 Record Views